U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, October 2014

It is estimated that nearly 1.7 million people in the United States (U.S.) will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease.  Despite advancements in oncology (the branch of medicine that deals with cancer), the disease remains the second-leading cause of death in the country after heart disease.  Today, a constellation of methods are used in the fight against cancer, including diagnostic imaging modalities such as magnetic resonance imaging (MRI) and nuclear/molecular medicine imaging (NMMI), which allow physicians to detect malignancies at their most treatable stages.

In the U.S., approximately 15.1 million diagnostic oncology-related MRI and NMMI procedures were performed in 2013.  Together, these procedures generated approximately $595.9 million in corresponding systems sales; it is expected that during the forecast period covered by this report, sales of these systems for diagnostic oncology-related indications will increase at a compound annual rate of 5.5%, reaching an estimated $780.1 million in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.  

Covered topics in this report include a statistical overview of cancer in the U.S. including cancer incidence and prevalence, cancer-related deaths, and cancer risk factors; MRI applications and indications; MRI computer-aided detection; MRI systems including bore-less, enclosed, flared-gantry, intraoperative, open, and wide-bore models; NMMI applications and indications; positron emission tomography (PET) and hybrid PET systems; radioisotope/radiopharmaceutical shortages; single-photon emission computed tomography (SPECT) and hybrid SPECT systems, total and diagnostic oncology-related MRI and NMI procedures volumes and market forecasts, among others.